Nintedanib for the treatment of idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies

(2017) Daniele Magnini et al.   RESPIRATION

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

(2017) Luca Richeldi et al.   THORAX

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

(2017) Steven D Nathan et al.   Lancet Respiratory Medicine

Role of pirfenidone in the management of pulmonary fibrosis

(2017) Keith Meyer et al.   Therapeutics and Clinical Risk Management

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS

(2016) Ulrich Costabel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

(2016) Claudia Dallinger et al.   JOURNAL OF CLINICAL PHARMACOLOGY

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

(2016) Wim A. Wuyts et al.   LUNG

Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis

(2016) Paola Rogliani et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

(2016) Francesco Bonella et al.   RESPIRATION

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

(2016) Luca Richeldi et al.   RESPIRATORY MEDICINE

Pharmacological management of IPF

(2016) Raphael Borie et al.   RESPIROLOGY

Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials

(2016) Arata Azuma et al.   RESPIROLOGY

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

(2016) Martin Kolb et al.   THORAX

Early lung surveillance of cystic fibrosis: what have we learnt?

(2016) Rachel E Foong et al.   Expert Review of Respiratory Medicine

Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis

(2016) Jun Fukihara et al.   Expert Review of Respiratory Medicine

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

(2015) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF

(2015) Katrin Milger et al.   EUROPEAN RESPIRATORY JOURNAL

The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis

(2015) Friedrich Grimminger et al.   EUROPEAN RESPIRATORY JOURNAL

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor

(2015) Martin Reck   Expert Review of Anticancer Therapy

Nintedanib: From Discovery to the Clinic

(2015) Gerald J. Roth et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology

(2015) Sohita Dhillon   Targeted Oncology

Nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Mariano E. Mazzei et al.   Therapeutic Advances in Respiratory Disease

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

(2014) Takashi Ogura et al.   EUROPEAN RESPIRATORY JOURNAL

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11

(2014) Ganesh Raghu et al.   Lancet Respiratory Medicine

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

(2014) Wim A Wuyts et al.   Lancet Respiratory Medicine

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

(2011) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

(2011) Peter Stopfer et al.   XENOBIOTICA

Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

(2010) Brett Ley et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Targeting non-malignant disorders with tyrosine kinase inhibitors

(2010) Friedrich Grimminger et al.   NATURE REVIEWS DRUG DISCOVERY

The pathogenesis of idiopathic pulmonary fibrosis

(2010) William R. Coward et al.   Therapeutic Advances in Respiratory Disease

Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)

(2009) Gerald J. Roth et al.   JOURNAL OF MEDICINAL CHEMISTRY

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH